caa a22 4500 477125816 CHVBK 20180405111649.0 cr unu---uuuuu 170330e19970601xx s 000 0 eng 10.1023/A:1012171010492 doi (NATIONALLICENCE)springer-10.1023/A:1012171010492 Development of a Novel Controlled-Release System for Gastric Retention [Elektronische Daten] [Arati Deshpande, Navnit Shah, Christopher Rhodes, Waseem Malick] Purpose. We report on the development of a novel controlled-release gastric retention system, which consists of a matrix tablet, coated with a permeable membrane. When immersed in simulated gastric fluid, the tablet expands. The tablet remains expanded for eighteen to twenty hours, during which time the drug is released. The tablet then either disintegrates into fragments or loses its integrity. Methods. Tablets containing a soluble drug (chlorpheniramine maleate, i.e., CPM) and a poorly soluble drug (riboflavin 5′ phosphate, i.e., R5′P) were compressed. They were coated with a permeable and elastic polymer (Eudragit®). Dissolution profiles of these tablets were studied. The changes in the pH, viscosity, and deformation characteristics as a function of time were measured. Results. Carbopol® provided a firm structure to the swollen tablet. Polyvinyl pyrrolidone XL (PVP XL) contributed to the swelling of the tablet. Carbonates provided the initial alkaline micro-environment for Carbopol® to gel and conferred buoyancy to the tablet. Coating provided the support needed for the core to remain intact during drug release and, at the same time, it allowed drug release due to its permeable nature. During release, the gelling properties of Carbopol® lessened, resulting in a decrease in the firmness of the core. This was evident from the decrease in the viscosity of the core. The energy required at 50% strain also decreased as the drug release progressed. Conclusions. When this tablet is ingested, the chances of its elimination through the pylorus should be greatly reduced due to tablet's expansion, and due to its disintegration or loss in integrity it should then be expelled out of the stomach at the end of the drug release. Plenum Publishing Corporation, 1997 controlled-release nationallicence gastric retention nationallicence floating nationallicence swelling nationallicence matrix nationallicence Deshpande Arati Dept. of Pharmaceutics, University of Rhode Island, 02881, Kingston, Rhode Island, USA aut Shah Navnit Hoffman-La Roche, 07110, Nutley, New Jersey, USA aut Rhodes Christopher Dept. of Pharmaceutics, University of Rhode Island, 02881, Kingston, Rhode Island, USA aut Malick Waseem Hoffman-La Roche, 07110, Nutley, New Jersey, USA aut Pharmaceutical Research Kluwer Academic Publishers-Plenum Publishers 14/6(1997-06-01), 815-819 0724-8741 14:6<815 1997 14 11095 https://doi.org/10.1023/A:1012171010492 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1012171010492 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Deshpande Arati Dept. of Pharmaceutics, University of Rhode Island, 02881, Kingston, Rhode Island, USA aut NATIONALLICENCE 700 1- Shah Navnit Hoffman-La Roche, 07110, Nutley, New Jersey, USA aut NATIONALLICENCE 700 1- Rhodes Christopher Dept. of Pharmaceutics, University of Rhode Island, 02881, Kingston, Rhode Island, USA aut NATIONALLICENCE 700 1- Malick Waseem Hoffman-La Roche, 07110, Nutley, New Jersey, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Kluwer Academic Publishers-Plenum Publishers 14/6(1997-06-01), 815-819 0724-8741 14:6<815 1997 14 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 219988463 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer